Karyopharm Therapeutics Inc.
Symbool: KPTI
NASDAQ
1.37
USDMarktprijs vandaag
-0.9064
Koers/Winst Verhouding
-0.0160
Koers/Winst Groei Verhouding
157.64M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Karyopharm Therapeutics Inc. (KPTI) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 897.57 | 192.1 | 278 | 228.6 | |||||||||||||
balance-sheet.row.short-term-investments | 636.07 | 139.2 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.net-receivables | 132.37 | 27 | 47.1 | 22.5 | |||||||||||||
balance-sheet.row.inventory | 13.65 | 3 | 4.2 | 4.1 | |||||||||||||
balance-sheet.row.other-current-assets | 226.73 | 11.8 | 19.8 | 2.9 | |||||||||||||
balance-sheet.row.total-current-assets | 1069.53 | 233.9 | 326.8 | 258.1 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 23.05 | 4.9 | 7.4 | 1.6 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-investments | 1.7 | 0.3 | 0.6 | 0.6 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.other-non-current-assets | 39.74 | 1.3 | 23.4 | 44.9 | |||||||||||||
balance-sheet.row.total-non-current-assets | 64.5 | 6.5 | 31.4 | 47.2 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.account-payables | 15.4 | 3.1 | 2.8 | 1.6 | |||||||||||||
balance-sheet.row.short-term-debt | 12.56 | 3.3 | 2.9 | 2.3 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 686.92 | 170.9 | 170.1 | 169.3 | |||||||||||||
Deferred Revenue Non Current | 530.39 | 132.5 | 132.7 | 133 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -395.13 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 172.27 | 63 | 60.3 | 0.7 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 1358.64 | 307.2 | 374.8 | 385 | |||||||||||||
balance-sheet.row.other-liabilities | -123.63 | 0 | -65.9 | -73.7 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 25.52 | 2.8 | 9 | 11.3 | |||||||||||||
balance-sheet.row.total-liab | 1487.05 | 376.6 | 374.8 | 385 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.05 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.retained-earnings | -5721 | -1487 | -1343.9 | -1178.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.1 | -0.2 | -0.6 | 0.2 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5370.03 | 1351 | 1327.9 | 1098.8 | |||||||||||||
balance-sheet.row.total-stockholders-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1134.03 | - | - | - | |||||||||||||
Total Investments | 636.37 | 139.5 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.total-debt | 696.11 | 177 | 173 | 169.3 | |||||||||||||
balance-sheet.row.net-debt | 434.6 | 124.1 | 37.8 | -21.2 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.6 | 0.8 | |||||||||||||
cash-flows.row.deferred-income-tax | 5.92 | -1.1 | 0 | 1.5 | |||||||||||||
cash-flows.row.stock-based-compensation | 21.71 | 21.7 | 35.4 | 29.8 | |||||||||||||
cash-flows.row.change-in-working-capital | 31.41 | 31.4 | -20 | -23.2 | |||||||||||||
cash-flows.row.account-receivables | 20.12 | 20.1 | -5.1 | -9.6 | |||||||||||||
cash-flows.row.inventory | 1.18 | 1.2 | -0.1 | -1.5 | |||||||||||||
cash-flows.row.account-payables | 0.35 | 0.3 | 1.2 | -2.8 | |||||||||||||
cash-flows.row.other-working-capital | -0.7 | 9.8 | -16 | -9.3 | |||||||||||||
cash-flows.row.other-non-cash-items | -9.19 | -2.2 | -0.3 | 8.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -92.72 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 104.3 | 5.5 | |||||||||||||
cash-flows.row.purchases-of-investments | -159.15 | -159.2 | -226 | -45.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 167.09 | 167.1 | 121.9 | 192.8 | |||||||||||||
cash-flows.row.other-investing-activites | -18.9 | 0 | -104.3 | -5.5 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 7.94 | 7.9 | -104.3 | 141.8 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -60 | |||||||||||||
cash-flows.row.common-stock-issued | 1.12 | 1.1 | 189.8 | 9.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 1.12 | 1.1 | 4 | 123.7 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 39.69 | 1.1 | 193.7 | 73.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.03 | 0 | -0.5 | 0 | |||||||||||||
cash-flows.row.net-change-in-cash | -83.61 | -83.4 | -60.6 | 108.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 264.86 | 52.9 | 136.9 | 197.4 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 348.48 | 136.3 | 197.4 | 89.1 | |||||||||||||
cash-flows.row.operating-cash-flow | -92.72 | -92.7 | -149.6 | -107.1 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.free-cash-flow | -92.72 | -92.7 | -149.7 | -112.8 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 146.03 | 146 | 157.1 | 209.8 | |||||||||||||
income-statement-row.row.cost-of-revenue | 5.02 | 5.5 | 5.2 | 3.4 | |||||||||||||
income-statement-row.row.gross-profit | 141.01 | 140.6 | 151.9 | 206.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 138.67 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 131.88 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.operating-expenses | 270.55 | 270.1 | 294.1 | 304.7 | |||||||||||||
income-statement-row.row.cost-and-expenses | 275.57 | 275.6 | 299.3 | 308.1 | |||||||||||||
income-statement-row.row.interest-income | 10.94 | 10.9 | 2.4 | 0.6 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.total-operating-expenses | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.58 | 0.5 | 2.3 | 0.5 | |||||||||||||
income-statement-row.row.ebitda-caps | -121.1 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -129.54 | -129.5 | -142.2 | -98.3 | |||||||||||||
income-statement-row.row.income-before-tax | -142.78 | -142.8 | -164.9 | -123.8 | |||||||||||||
income-statement-row.row.income-tax-expense | 0.32 | 0.3 | 0.4 | 0.3 | |||||||||||||
income-statement-row.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 |
Vaak gestelde vragen
Wat is Karyopharm Therapeutics Inc. (KPTI) totale activa?
Karyopharm Therapeutics Inc. (KPTI) totale activa is 240438000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 69756000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.966.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.980.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.887.
Wat is Karyopharm Therapeutics Inc. (KPTI) nettowinst (netto-inkomen)?
De nettowinst is -143099000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 177016000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 270101000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 52891000.000.